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RESUMEN 
Objetivo: Analizar la confiabilidad y la va-
lidad de las propiedades psicométricas de 
la versión brasileña del instrumento de 
evaluación de síntomas, titulado Inventa-
rio de Síntomas del M.D. Anderson – core. 
Método: Estudio transversal del que parti-
ciparon 268 pacientes con cáncer en trata-
miento ambulatorio, del Municipio de Ijuí, 
Rio Grande do Sul, Brasil. Resultados: El Alfa 
de Cronbach MDASI general, los síntomas y 
las interferencias fueron respectivamente 
(0,857), (0,784) y (0,794).  El análisis fac-
torial demostró la adecuación de los datos 
(0,792). Se identificaron cuatro factores de 
los principales componentes relacionados 
con los síntomas. Factor I: problemas de 
sueño, preocupaciones, dificultades de re-
cordar las cosas y tristeza. Factor II: mareo, 
náuseas, falta de apetito y vómito. Factor III: 
somnolencia, boca seca, adormecimiento 
y hormigueo.  Factor IV: dolor, fatiga y fal-
ta de aliento. Se evidenció un solo factor 
en el componente interferencias en la vida 
(0,780), prevaleciendo para la actividad en 
general (59,7%), trabajo (54,9%) y para ca-
minar (49,3%). Conclusión: La versión bra-
sileña del Inventario de M.D. Anderson-core 
mostró propiedades psicométricas adecua-
das en la población evaluada.
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RESUMO 
Objetivo: Analisar a confiabilidade e a va-
lidade das propriedades psicométricas da 
versão brasileira do instrumento de ava-
liação de sintomas, intitulado Inventário 
de Sintomas do M.D. Anderson – core. 
Método: Estudo transversal do qual par-
ticiparam 268 pacientes com câncer em 
tratamento ambulatorial, do Município de 
Ijuí, Rio Grande do Sul, Brasil. Resultados: O 
Alfa de Cronbach MDASI geral, os sintomas 
e as interferências foram respectivamente 
(0,857), (0,784) e (0,794).  A análise fatorial 
demonstrou adequação dos dados (0,792). 
Identificaram-se quatro fatores dos princi-
pais componentes relacionados aos sinto-
mas. Fator I: problemas de sono, preocupa-
ções, dificuldades de lembrar-se das coisas 
e tristeza. Fator II: enjoo, náuseas, falta de 
apetite e vômito. Fator III: sonolência, boca 
seca, dormência e formigamento.  Fator IV: 
dor, fadiga e falta de ar. Evidenciou-se um 
único fator no componente interferências 
na vida (0,780), prevalecendo para ativi-
dade em geral (59,7%), trabalho (54,9%) e 
para caminhar (49,3%). Conclusão: A versão 
brasileira do Inventário de M.D. Anderson-
core mostrou propriedades psicométricas 
adequadas na população avaliada.
DESCRITORES
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ABSTRACT 
Objective: To analyze the reliability and 
validity of the psychometric properties of 
the Brazilian version of the instrument for 
symptom assessment, titled MD Anderson 
Symptom Inventory – core. Method: A 
cross-sectional study with 268 cancer pa-
tients in outpatient treatment, in the mu-
nicipality of Ijuí, state of Rio Grande do Sul, 
Brazil. Results: The Cronbach’s alpha for 
the MDASI general, symptoms and inter-
ferences was respectively (0.857), (0.784) 
and (0.794). The factor analysis showed 
adequacy of the data (0.792). In total, were 
identified four factors of the principal com-
ponents related to the symptoms. Factor I: 
sleep problems, distress (upset), difficulties 
in remembering things and sadness. Factor 
II: dizziness, nausea, lack of appetite and 
vomiting. Factor III: drowsiness, dry mou-
th, numbness and tingling. Factor IV: pain, 
fatigue and shortness of breath. A single 
factor was revealed in the component of 
interferences with life (0.780), with preva-
lence of activity in general (59.7%), work 
(54.9%) and walking (49.3%). Conclusion: 
The Brazilian version of the MD Anderson 
Symptom Inventory - core showed adequa-
te psychometric properties in the studied 
population.
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INTRODUCTION
Cancer is a group of diseases that invariably causes 
many signs and symptoms on patients. It should be diag-
nosed and treated early by the therapeutic modalities to 
improve the clinical condition of patients, ensuring the 
possibility of therapeutic interventions against cancer 
and especially, of regaining quality of life with the control 
and/or eradication of the disease(1). The cancer treatment 
comprises surgery, radiation therapy (RT), chemotherapy 
(chemo), the hormone therapy and specific targeted ther-
apies, which may be used alone or conjugated(2).
Cancer is a disease of aggressive and progressive evo-
lution that may jeopardize the lives of patients in physi-
cal, psychological or social aspects(3). It has deleterious 
symptoms and prolonged treatment, associated with side 
effects of treatment and/or amputation/mutilation re-
sulting from surgical procedures(4). The symptoms are the 
result of a variety of conditions, whether socio-cultural, 
behavioral, psychological and physiological that occur 
individually or collectively(5) and also correlate with the 
changes experienced in daily activities(6).
The evaluation of symptoms is critical and allows 
identifying complications early, as well as minimizing or 
preventing possible changes in the functional capacity of 
patients. For that purpose, there are several instruments 
that measure individual or multiple symptoms. Among 
the instruments available in the literature, there is the MD 
Anderson Symptom Inventory - core (MDASI), an instru-
ment that assesses the severity of symptoms and their 
daily impact in the last 24 hours. It was initially developed 
in English in the United States(7).
The MDASI was linguistically and psychometrically 
validated in Japanese(8), Greek(9), Chinese(10), Russian(11), 
Korean(12), Thai(13), Filipino(14), Arabic(15) and French(16). 
However, in Brazil this instrument had only linguistic 
validation(5), which demonstrated the need for its psy-
chometric validation. Given the variability of symptoms 
presented by patients due to the illness and treatment, 
the assessment of multiple symptoms by the MDASI 
makes this instrument an important tool for clinical and 
research activities, justifying the intention of validating it 
for use in the Brazilian population.
From this context, this study aimed at assessing the 
reliability and validity of the psychometric properties 
of the Brazilian version of the MD Anderson Symptom 
Inventory – core (MDASI).
METHOD
This is a cross-sectional study carried out in the out-
patient Oncology High Complexity Center (CACON) of 
the Hospital de Caridade de Ijuí (HCI), in the municipality 
of Ijuí, state of Rio Grande do Sul (RS), Brazil. The study 
population consisted of 790 patients undergoing cancer 
treatment, residents in Ijuí/RS, who were registered in the 
CACON system.
The selection of participants was by convenience 
sampling, with data collection between July and Decem-
ber 2012. The inclusion criteria were the following: over 
eighteen years of age; patients with a diagnosis of cancer; 
residents of the city of Ijuí; and undergoing cancer treat-
ment for at least three months in a therapeutic modality 
that may be surgical, chemotherapy, hormone therapy, 
radiotherapy or combined. The patients excluded from 
the sample were the following: in the present condition 
of disease-free follow-up; with auto and allopsychic dis-
orientation that prevented them from responding to the 
instruments; those who were not aware of their cancer 
diagnosis, attested by the doctor or family member.
Patients were invited to join the study from their ap-
pointments in the unit for consultation or the completion 
of treatment. The instrument was completed by those 
responsible for data collection, after the participants ac-
cepted to take part in the study and signed the Informed 
Consent Form (ICF) in a room to ensure their privacy.
According to the selection criteria, 471 patients 
(59.6%) were excluded, a total eligible population of 319 
patients (40.4%). Among these, 268 (84%) participated in 
the study. The losses (n = 51, 16%) were due to death dur-
ing collection (n = 46, 90.2%), three (5.9%) did not attend 
the appointment (they were confined to bed at home) 
and two (3.9%) refused to participate in the study. In or-
der to check the statistical significance of the number of 
patients in the study, the following criteria were adopted: 
estimated proportion of 50%, sampling error of 5% and a 
significance level of 5%. From the sample size calculation, 
a minimum of 176 patients would be necessary.
The data collection was carried out by one of the au-
thors, a doctorate student in the study period, and also 
by previously trained nursing academics. The instrument 
used had closed questions regarding demographic, eco-
nomic and clinical characteristics (prepared by the re-
searchers), and the Brazilian version of the MD Anderson 
Symptom Inventory (MDASI) – core(5).
The Epi-Info® 6.04 software was used for organization 
of data that were independently double entered. After 
corrections of errors and inconsistencies, the statistical 
analysis was done using the Statistical Package for the So-
cial Sciences (SPSS) version 18.0 for windows. 
The categorical variables were expressed as absolute 
frequencies and proportions. The quantitative variables 
were described by measures of central tendency (mean 
or median) and dispersion (standard deviation or inter-
quartile range) according to the distribution of normality 
assessed by the Kolmogorov-Smirnov test. The intensity 
of the cancer symptoms (component 1) and their inter-
ference in the daily lives of these patients (component 2) 
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was assessed by the Brazilian version of MDASI after the 
authorization for using the instrument given by the MD 
Anderson Cancer Center, University of Texas, USA.
The component 1, intensity of symptoms in the last 
24 hours, has 13 items (pain, fatigue, dizziness and nau-
sea, sleep problems, distress (upset), dyspnea, difficulty 
in remembering things, lack of appetite, drowsiness, dry 
mouth, sadness, vomiting, numbness/tingling), evaluated 
on a scale of zero to 10, zero being no symptoms and 10 as 
bad as you can imagine. The component score is obtained 
by taking the average of 13 items. The total proportion 
score can be obtained when the patient marks at least 
seven of the 13 items, using the formula: (sum of items 
answered) X 13/number of items answered(7).
The component 2, symptoms that interfere with 
life, has six items (general activity, mood, work, relation-
ships, walking and enjoyment of life) also assessed on a 
numerical rating scale of zero to 10, zero being no inter-
ference and 10 interfered completely. The mean of the 
interference items can be used to represent the distress 
of general symptoms. This mean can be used if more than 
50% (four out of six items) are answered: (sum of an-
swered items) X 6 / number of answered items(7).
In order to assess the instrument dimensionality, was 
done an exploratory factor analysis of data by the method of 
principal components. The factorability of data was evaluated 
by the index of Kaiser-Meyer-Olkin (KMO), which indicates the 
proportion of data variance that are common to all variables. 
The following criteria were adopted to evaluate this test: 1.0 
to 0.9 very good; 0.9 to 0.8 good; 0.8 to 0.7 regular; 0.7 to 
0.6 reasonable; 0.6 to 0.5 weak; < 0.5 unacceptable(17). Sub-
sequently was used the technique of Varimax axis rotation.
In order to ensure that each item represented the 
underlying factor construct, a minimum charge factor 
of 0.35 was set to accept the item(18). The commonali-
ties for each item were also calculated. They are defined 
as the portion of item variance explained by the factors 
retained in the analysis. Values greater than or equal to 
0.40 are considered satisfactory(19). The scale accuracy was 
calculated by means of the Cronbach’s alpha coefficient.
The study project was authorized by the researched 
institution, approved by the Research Ethics Committee 
(CEP) of the Universidade Federal de São Paulo (UNIFESP) 
under number 47215 of June 29 2012, and complied with 
the desired ethical standards.
RESULTS
The studied population to validate the instrument for 
use in Portuguese was composed of 268 patients under-
going cancer treatment. Among these, 172 (64.2%) were 
women with a mean age of 61.5 ± 14.9 years. The level of 
education had the following variation: 13 (4.9%) unedu-
cated, 144 (53.7%) with incomplete primary education, 
27 (10.1%) completed primary education, 13 (4.9%) with 
incomplete secondary education, 40 (14.9%) completed 
secondary education, nine (3.4%) with incomplete higher 
education, 15 (5.6%) with complete higher education, sev-
en (2.6%) with complete post-graduate education.
A percentage of 28.4% of respondents were being 
treated for secondary tumor, and 51.8% were in stages III/
IV. Regarding the treatment they had already done or were 
undergoing, 77.6% were surgical, 48.1% were radiotherapy, 
70.5% adjuvant chemotherapy, and 33.2% neoadjuvant 
chemotherapy. In relation to the tumor location, 117 were 
breast cancer (43.7%), 39 prostate (14.6%), 20 were colon 
(7.5%), 13 head and neck (4.9%), nine were skin cancer 
(3.35%), eight anus (3.0%), eight lung (3.0%), seven were 
chronic myeloid leukemia (2.6%), four bladder (1.5%), four 
esophagus (1.5%), six cervix (2.2%), four ovarian (1.5%), 
three endometrial (1.1%), three were testicle cancer (1.1%), 
three pancreas (1.1%) and eight in other sites (3.5%).
The results of the KMO test showed the data adequa-
cy for factor ana’1lysis (0.792) that explained 56.6% of 
variance. Considering the 0.35 cutoff as the minimum 
load for including the item in the factor, were obtained 
four factors (Table 1). The factor I gathered the items: 
sleep problems, distress (upset), difficulty in remem-
bering things and sadness, with an eigenvalue of 3.684 
and explaining 16.5% of the total variance. The factor II 
was comprised of three items, namely: dizziness, nau-
sea, lack of appetite and vomiting, with an eigenvalue of 
1.41, explaining 31.4% of the total variance. The factor III 
was comprised of three items, namely: drowsiness, dry 
mouth, and numbness/tingling, with an eigenvalue of 
1.21, explaining 44% of the total variance. The factor IV 
was composed of the following three items: pain, fatigue 
and shortness of breath, with an eigenvalue of 1.06, ex-
plaining 56.65% of the total variance.
The reliability of the MDASI general symptoms was 
measured by Cronbach’s alpha that estimated 0.784. The 
specific alpha by factor ranged from 0.662 to 0.697. The 
exclusion of any item did not substantially alter the result.
Table 1 – Analysis of the principal components of MDASI symptoms, varimax rotation and Cronbach’s alpha - Ijuí, RS, Brazil, 2012
What is the intensity of your symptoms?
Main Components
Factor I Factor II Factor III Factor IV h2*
1.    Pain 0.251 0.010 0.249 0.613 0.501
2.    Fatigue 0.166 0.131 0.156 0.680 0.532
3.    Dizziness and nausea 0.139 0.766 0.060 0.239 0.666
4.    Sleep problems 0.552 0.127 0.269 0.205 0.435
5.    Distress (upset) 0.822 0.115 0.028 0.126 0.706
Continue...
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Table 2 – Analysis of the principal components of the MDASI 
Interferences - Ijuí, RS, Brazil, 2012
MDASI 
Interferences Factor 1 h2*
Activity in general 0.785 0.615
Mood 0.740 0.547
Work 0.731 0.534
Relationships 0.691 0.477
Walking 0.543 0.294
Enjoyment of life 0.726 0.528
Cronbach’s alpha --- 0.794**
Note: Extraction method – Analysis of the principal component. * h2: 
Commonality. ** Overall
Tabela 3 -  Descriptive statistics of the symptoms reported in the last 24 hours and their interference in the daily life of patients un-
dergoing cancer treatment - Ijuí, RS, Brazil, 2012
MDASI*
Prevalence
Mean SD
Percentile
N % 25 50 75
Symptoms
Pain 122 45.5 2.51 3.15 0 0 5
Fatigue 169 63.1 3.52 3.26 0 4 6
Feeling sick (nausea) 54 20.1 1.20 2.65 0 0 0
Sleep problems 99 36.9 2.40 3.43 0 0 5
Distress (upset) 146 54.7 3.36 3.64 0 2 6
Shortness of breath 50 18.7 0.99 2.37 0 0 0
Difficulty in remembering things 150 56.2 3.11 3.37 0 2 5
Lack of appetite 87 32.5 1.74 2.91 0 0 3
Drowsiness 126 47.2 2.63 3.21 0 0 5
Dry mouth 146 54.9 3.34 3.63 0 2 7
Sadness 120 45.1 2.71 3.47 0 0 5
Vomiting 18 6.7 0.45 1.82 0 0 0
Numbness and tingling 109 40.7 2.51 3.52 0 0 5
Interference 
Activity in general 160 59.7 3.97 3.77 0 4 8
Mood 116 43.3 2.60 3.43 0 0 5
Work 147 55.1 3.77 3.87 0 3 8
Relationships 59 22.1 1.48 3.06 0 0 0
Walking 132 49.4 3.21 3.77 0 0 7
Enjoyment of life 86 32.1 2.07 3.41 0 0 5
*M.D. Anderson symptoms inventory
Continuation...
The KMO (0.780) was obtained from the principal 
component analysis, showing the existence of a single fac-
tor that explained 49.9% of the variance. The factor analy-
sis with oblique rotation showed that the factor found is 
composed of six items (Table 2).
The reliability of the MDASI interferences of symptoms 
in the last 24 hours was 0.794. The exclusion of any item 
did not substantially alter the result. The Cronbach’s alpha 
evaluation of the overall MDASI (symptoms and interfer-
ence) was 0.857.
When assessing to which extent the symptoms were 
interfering in the lives of respondents, the highest 
prevalence for interference were the following items: 
activity in general (59.7%), work (54.9%) and walking 
(49.3). The averages were (3.97±3.77), (3.77±3.87) and 
(3.21±3.77), respectively.
The median of the factors that interfere in the lives 
of patients showed that for 50% of respondents, inter-
ference was grade 4 in relation to daily activities and 
grade 3 for interference at work. These data can be 
analyzed in Table 3.
What is the intensity of your symptoms?
Main Components
Factor I Factor II Factor III Factor IV h2*
6.    Shortness of breath 0.005 0.100 -0.024 0.785 0.627
7.    Difficulty in remembering things 0.512 -0.001 0.245 0.076 0.328
8.    Lack of appetite 0.123 0.712 0.164 0.071 0.554
9.    Drowsiness 0.117 0.268 0.642 0.073 0.503
10.  Dry mouth 0.053 0.161 0.696 0.229 0.566
11. Sadness 0.833 0.215 0.035 0.064 0.745
12. Vomiting 0.086 0.795 0.057 -0.014 0.642
13. Numbness and tingling 0.243 -0.084 0.702 0.032 0.560
Cronbach’s alpha 0.697 0.671 0.655 0.662 0.784**
Note: Rotation method: Varimax with Kaiser normalization.
* h2: Commonality. ** Overall.
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With regard to symptoms, 50% of respondents rated 
the fatigue as intensity 4 (in a score of 0-10); being dis-
tressed (upset) and the feeling of dry mouth as grade 2 
of intensity. The symptoms with highest prevalence were 
fatigue (63.1%), difficulty in remembering things (56.2%), 
distress (upset) (54.5%) and dry mouth (54.5%). These 
symptoms also had the highest mean values: 3.52 (±3.26), 
3.11 (±3.37), 3.36 (±3.64) and 3.34 (±3.63), respectively.
DICUSSION
The identification of multiple symptoms is of essen-
tial importance for patients, hence, health professionals 
should make use of instruments that measure such symp-
toms as the MDASI, which can be applied to homoge-
neous or heterogeneous samples(20). The symptoms are 
prevalent and severe in patients with cancer. Any clinical 
study to evaluate the impact of treatment should consider 
the assessment of symptoms, mainly in patients at ad-
vanced stages of disease(21).
The analyzes carried out to test the reliability of the in-
strument were satisfactory (alpha≥0.70) in its two compo-
nents, the MDASI symptoms and interferences, confirming 
the instrument reliability. The exclusion of any item did not 
substantially alter the result, tested by the Cronbach’s alpha.
The findings regarding the psychometric properties 
of the MDASI are consistent with the findings of previous 
studies published with samples from other countries and 
other cultures. In the validation of the MDASI for the Chi-
nese language, the researchers obtained the Cronbach’s 
alpha results of 0.86, 0.84 and 0.90 for the instrument 
in general, symptoms and interferences, respectively(10). 
Similarly, in this study, the exclusion of any item did not 
result in significant changes.
The initial assumption was that the MDASI Symptoms 
and the MDASI Interference were formed by a single fac-
tor each. However, the factor analysis of the MDASI Symp-
toms produced four factors: factor I, covering the symp-
toms of sadness, distress (upset), sleep problems and 
difficulty in remembering things; factor II, with the signs 
and symptoms of vomiting, dizziness/nausea and lack of 
appetite; factor III, with symptoms of numbness/tingling, 
dry mouth, drowsiness; and factor IV, with shortness of 
breath, fatigue and pain.
The original study in English identified two factors: one 
comprising the general symptoms (fatigue, pain, dyspnea, 
difficulty in remembering things, distress (upset), numb-
ness/tingling, dry mouth, sadness, insomnia and drowsi-
ness), with Cronbach’s alpha = 0.85; and another factor 
was related to gastrointestinal symptoms (nausea and 
vomiting), with Cronbach’s alpha = 0.82(7).
Comparing the findings of the current study with the val-
idations of MDSI-core of Japanese(8) and American(7) studies, 
it was found that emotional symptoms such as distress (up-
set) and sadness are rarely addressed in practice during 
consultations, although strongly present and associated 
with physical symptoms, such as fatigue, pain, drowsiness, 
dizziness, among others. The convergence of findings indi-
cates that the occurrence of emotional symptoms is quite 
independent from the cultural characteristics of citizenship 
of patients. Such findings should expand the clinical evalua-
tion that invariably favors the physical symptoms and does 
not associate their severity with the emotional responses 
that may be influencing in their genesis or aggravation.
In the present study, the analysis of the principal com-
ponents of the MDASI Interferences resulted exclusively 
in only one factor, unlike the Greek study(9) with three fac-
tors, and the American(7) with two factors. The features 
that suffered greater interference were the activity in gen-
eral, work and locomotion, aggravated by the symptoms 
of fatigue, difficulty in remembering things, distress (up-
set) and dry mouth. The symptoms of greater interference 
in the assessed items were distress (upset) in the Greek 
study(9), and fatigue and sadness in the Japanese study(8).
The clinical oncology treatments are known to pro-
duce plurality of symptoms including fatigue, pain, dis-
turbed sleep, distress (upset), and loss of appetite, which 
may vary over treatment. Such symptoms can be severe 
and extremely debilitating(22), particularly when associ-
ated with advanced stages of disease, as in the case of 
the studied population. Thus, the higher the impairment 
of the clinical functional capacity, the lower the patient’s 
ability to perform activities of life(14).
In the national study, the entire sample had already 
undergone a type of treatment, and for a third, the cur-
rent situation was disease relapse. This allows analyzing 
that the respondents amounted favorable clinical condi-
tions to obtain conclusive data on the evaluation of their 
signs and symptoms. However, they have also denoted 
significant impairment of their general functions, includ-
ing mobility and work capacity.
CONCLUSION
The Brazilian version of the MD Anderson – core 
proved to be valid and reliable for the Brazilian reality in 
the context of the region in which it was assessed.
The results regarding the validity and reliability of the 
MDASI give additional support to the applicability of the 
instrument in research in oncology. Future studies may be 
carried out to assess multiple symptoms and interference 
in life over the last 24 hours, offering new perspectives to 
discuss this subject, aiming at improving the management of 
symptoms in these patients. It is recommended to validate 
the instrument with patients from other Brazilian regions.
Study limitations: The findings are relevant to a particular 
population group, with its social, cultural, economic confor-
mation, and within the own SUS care, which has the same 
features and potentialities in every region of the country.
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